
Abingworth completes succession

Stephen Bunting has stepped down from his role as head of Abingworth to become chairperson, replaced by Tim Haines and Kurt von Emster as joint managing partners.
Bunting has been managing partner of Abingworth since 2002. Following his transition he will remain as active member of the firm, working in a full-time capacity.
Haines joined Abingworth in 2005 as partner. Prior to that he was CEO of Abingworth portfolio company Astex Therapeutics, where he spent five years building up the company. Previously, Haines was CEO of two divisions of publicly listed medical technology company Datascope Corp. Other former senior roles include CEO of Thackray and general manager of Baxter UK.
Current and past board positions include Astex Pharmaceuticals, Fovea, Kspine, Lomboard Medical, Pixium Vision, PowderMed, Sientra, Stanmore Implants and XCounter.
Von Emster joined the life sciences- and healthcare-focused GP in January 2015 as partner. Based in Menlo Park, he was previously a co-founder of US investment firm venBio. He has also worked with MPM Capital and Franklin Templeton.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater